Loading
Insider filings for PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) are scarce in the SEDI feed, the latest one published on 13 January 2023. This page will fill in as new trades are disclosed. Source: insider filings from SEDI. Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
17 of 17 declarations
PsyBio Therapeutics Corp. is a company focused on developing psychedelic treatments for mental health disorders. It previously operated under the name Leo Acquisitions Corp.